Chembio Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
Chembio Diagnostics, Inc. (CEMI) announced it will release its financial results for Q4 and the full year 2020 on March 11, 2021, after trading closes. The management will host a conference call at 4:30 p.m. ET for investors to discuss these results. Interested parties can access the call by phone or through the company’s website. Chembio specializes in point-of-care diagnostics for infectious diseases, including COVID-19, and utilizes its innovative DPP technology for broad market applications.
- Chembio's focus on point-of-care diagnostics may attract significant market interest.
- Company's DPP technology offers broad market applications beyond infectious diseases.
- No specific financial metrics or guidance provided, creating uncertainty for investors.
HAUPPAUGE, N.Y., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2020 after the close of trading on Thursday, March 11, 2021.
The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 663365 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 40186 or by accessing www.chembio.com/investors/calendar-of-events/.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark, and the Chembio logo is Chembio’s trademark. For convenience, these trademarks appear in this release without ® or ™ symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademarks.
| Investor contact: |
| Philip Taylor Gilmartin Group (415) 937-5406 investor@chembio.com |
FAQ
When will Chembio Diagnostics release its Q4 2020 financial results?
What time is the conference call for Chembio's financial results?
What is Chembio Diagnostics' stock symbol?
What technologies does Chembio Diagnostics focus on?
